Allison Wey, VP of IR for Durata Therapeutics through its acquisition by Actavis, has moved to Regulus Therapeutics as VP of IR and corporate communications.
COO Jay Hagan said Wey's experience will be valuable as the publicly traded company's pipeline matures. Regulus is focused on microRNA therapeutics and developing treatments for chronic hepatitis C virus and Alport syndrome, among others.
Earlier, she was VP of IR and corporate affairs at Par Pharmaceuticals, departing on its acquisition by TPG. She was also VP of IR for Boren.
On the agency side, Wey was a senior VP at Edelman Financial and managing director for financial communications at Hill+Knowlton Strategies after starting out in finance.
Why CEO visibility is no longer optional as a communications tactic.
The “waiting period” that was once set aside for CEOs to develop their strategies before facing media scrutiny may be better used for corporate comms leaders get to know their CEO and what his or her short-term priorities will be.
Senior-most communications executives in the Fortune 500 earned between $50,000 and $100,000 more this year than they did two years ago, according to a recent survey of chief communications officers.
